ManagedCareHemo.com Presents: Collaborating to Improve Care for Hemophilia: Managed Care Strategies for the Evolving Treatment Paradigm Web Activity

• Release Date: July 1, 2021
• Expiration Date: January 1, 2023
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

EXPERT FACULTY

James T. Kenney, RPh, MBA Founder and President JTKENNEY, LLC Click here for biography Vanita Pindolia, PharmD, BCPS, MBA (Formerly) Vice President, Ambulatory Clinical Pharmacy Programs_PCM Henry Ford Health System/Health Alliance Plan of Michigan Click here for biography Mark T. Reding, MD Associate Professor of Medicine Director, Center for Bleeding and Clotting Disorders University of Minnesota Medical Center Click here for biography

Target Audience

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for hemophilia patients including: physicians, pharmacists, registered nurses.

Statement of Need/Program Overview 

Hemophilia is a rare, congenital bleeding disorder characterized by spontaneous and potentially life-threatening bleeding episodes. The most prevalent form, hemophilia A, affects clotting factor VIII, while hemophilia B is associated with a factor IX deficiency. There is currently no cure for hemophilia. People living with this disease may require multiple infusions of clotting factors each week as a prophylactic therapy, as well as emergency treatment in case of an acute injury. Still, patients experience repeated, often spontaneous, bleeding episodes, and in 30% of severe hemophilia A cases, they develop inhibitory antibodies against the replacement factor, that make these patients unresponsive to standard therapy. Successful management of hemophilia is often dependent on highly specialized, coordinated multidisciplinary care among providers, patients, and payers. To effectively address all of the clinical and administrative barriers to optimal hemophilia management, managed care and specialty pharmacy professionals require comprehensive education that increases knowledge and competence in several key areas.

Educational Objectives 
After completing this activity, the participant should be better able to:

• Describe recent insights into the safety, efficacy, and unique attributes of recently approved and emerging hemophilia treatment options.
  
• Assess the integration of the evolving treatment paradigm within the current hemophilia treatment algorithm.
  
• Explain hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences.
  
• Apply processes for managed care and specialty pharmacy professionals to improve communication and collaboration with HTCs.

Accreditation Statement 

Credit Designation:
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-21-2835-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

The PIM planners and others have nothing to disclose.
The NHF planners and others have nothing to disclose.
The Impact Education, LLC® planners and others have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:

1. Complete the evaluation form
2. A CE certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

FEE INFORMATION
There is no fee for this educational activity.